Understanding how pulmonary arterial hypertension affects muscle mass
Official title: Unraveling the systemic manifestations of pulmonary arterial hypertension on lean muscle mass
Funded at University of Pennsylvania · NIH-10859459 · Data updated 2026-11-12
This study is looking at how pulmonary arterial hypertension (PAH) affects muscle mass in patients, aiming to find out who might have low muscle mass and why, so we can better understand how it impacts their health and daily life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $729,818 |
| NIH project number | 1R01HL173533-01 |
| Project ID | NIH-10859459 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those experiencing symptoms related to muscle weakness or low lean mass.
✕Less likely to help
Patients without a diagnosis of pulmonary arterial hypertension or those who do not exhibit issues with muscle mass may not benefit from this research.
What this research studies
This research investigates the impact of pulmonary arterial hypertension (PAH) on lean muscle mass, a critical aspect often overlooked in patients with this condition. By examining a group of PAH patients, the study aims to identify those with low muscle mass and explore the underlying metabolic factors contributing to this issue. The research will utilize advanced techniques to assess muscle composition and its relationship with overall health outcomes, including quality of life and physical activity levels. Patients will be evaluated for various factors, including body composition and the role of fat tissue in muscle loss.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of muscle loss in patients with pulmonary arterial hypertension, potentially enhancing their quality of life.
How similar studies have gone: Previous research has indicated that addressing muscle mass loss in chronic conditions can lead to significant improvements in patient outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Al-Naamani, Nadine — University of Pennsylvania
- Study coordinator: Al-Naamani, Nadine
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.